Consensus $238.89M. Raises FY25 adjusted EBITDA view to breakeven to loss of $2M from loss of $5M-$9M.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health to present RWE on behavior change program at ObesityWeek
- Omada Health, Inc.: Strategic Growth and Market Penetration Drive Buy Rating
- Omada Health appoints Tsang as Chief Medical Officer
- Omada Health price target raised to $28 from $24 at Barclays
- Omada Health’s Surge in App Downloads and GLP-1 Care Track Expansion Justify Buy Rating